Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation

Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation

Abstract To evaluate the efficacy and safety of Risperidone ISM® against placebo in patients with acute exacerbation of schizophrenia. A multicenter, randomized, double-blind, placebo-controlled study was conducted between June 2017 and December 2018 (NCT03160521). Eligible patients received once-mo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christoph U. Correll, Robert E. Litman, Yuriy Filts, Jordi Llaudó, Dieter Naber, Ferran Torres, Javier Martínez
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Psychiatry
RC435-571
Acceso en línea:https://doaj.org/article/485f9847ecae4df6ad9a103f3ac27f37
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares